Stockscreener 앱 받기
1.6042
0.31%
0.0058
전일 마감가:
$1.61
열려 있는:
$1.64
하루 거래량:
37,578
Relative Volume:
0.11
시가총액:
$28.41M
수익:
-
순이익/손실:
$-22.70M
주가수익비율:
-0.461
EPS:
-3.4798
순현금흐름:
$-16.66M
1주 성능:
+0.31%
1개월 성능:
+38.63%
6개월 성능:
-57.83%
1년 성능:
-86.72%
1일 변동 폭
$1.60
$1.65
1주일 범위
$1.525
$1.69
52주 변동 폭
$0.89
$12.68
Cel-Sci Corp. Stock (CVM) Company Profile
명칭
Cel-Sci Corp.
전화
703-506-9460
주소
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
1.615 | 25.68M | 0 | -22.70M | -16.66M | -3.4798 |
VRTX
Vertex Pharmaceuticals Inc
|
553.87 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
848.52 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,046.72 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
148.99 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-01-13 | 개시 | H.C. Wainwright | Buy |
| 2015-03-02 | 개시 | Dawson James | Buy |
Cel-Sci Corp. 주식(CVM)의 최신 뉴스
Cel-Sci (CVM) Outlook: Ends Up by 3.14% at $1.64 for the Current Session; Key Range: the Price Remains Bounded by the Supplied Support and Resistance at the CloseHagopian Line - vinanet.vn
CEL-SCI Company Profile & Introduction - Moomoo
CEL-SCI Q3 Results: Per-share loss narrows 65% YoY to $(0.47) - scanx.trade
Cel-Sci shareholders elect directors and approve compensation plans at annual meeting - Investing.com
CEL SCI director granted 110K options at $1.49 | CVM Insider Trading - Stock Titan
CEL-SCI director granted 110K options at $1.49 | CVM Insider Trading - Stock Titan
CEL-SCI (NYSE: CVM) awards CEO 300,000 options over 3 years - Stock Titan
CEL-SCI (NYSE: CVM) awards Cipriano 80K options vesting over 3 years - Stock Titan
CEL-SCI (CVM) awards CSO Talor Eyal 250,000 stock options - Stock Titan
Form 8K CEL-SCI Corp For: 17 August By Investing.com - Investing.com Nigeria
CEL-SCI (NYSEAMERICAN: CVM) CFO lands new 2036 stock option grant - Stock Titan
CEL-SCI (CVM) Advances Multikine Trial Amid Low Valuation and Gu - GuruFocus
CEL-SCI Reports Fiscal Third Quarter 2026 Results - Yahoo Finance
CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month - Stocktwits
Cel-Sci: Fiscal Q3 Earnings Snapshot - marketscreener.com
CEL-SCI (CVM) faces going concern risk amid $16.6M loss and $6.5M cash - Stock Titan
CEL-SCI Corp (CVM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CEL-SCI Corp (CVM) Stock News Today - tradingkey.com
CEL-SCI publishes study on Multikine cancer treatment biomarkers - Investing.com
CEL-SCI (CVM) Advances Oral Cancer Immunotherapy Amid Challengin - GuruFocus
Before surgery, Multikine cut disease-progression risk 49% in study - Stock Titan
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study - Yahoo Finance
CEL-SCI study on Multikine in oral cancer accepted for publication - Investing.com
CEL-SCI Corp (CVM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CEL-SCI Corp (CVM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CEL-SCI Corp (CVM) Institutional Confidence - TradingKey
CEL-SCI Corp (CVM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CEL-SCI Corp (CVM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CEL-SCI Corp (CVM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CVM|CEL-SCI Corp|Price:1.180|Chg%:+0.010 - TradingKey
CEL-SCI Corp (CVM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CEL-SCI Corp (CVM) Balance Sheet - TradingKey
TradingKey - TradingKey
CVM|CEL-SCI Corp|Price:1.720|Chg%:+0.105 - TradingKey
Cel-Sci Corporation Q4 2024 Earnings: Narrowed Loss Beats Estimates as Clinical Pipeline AdvancesRevenue Guidance Range - dars.gov.et
$1.155 | Cel-Sci Corporation (CVM) Stock Price Today - Binance
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
CEL-SCI launches confirmatory study for head and neck cancer drug - Investing.com
CEL-SCI (CVM) Initiates Global Study for Multikine in Head and N - GuruFocus
Cancer drug Multikine heads into 212-patient global trial for head and neck tumors - Stock Titan
Why Did CEL-SCI Stock Plunge After Its Latest Offering - Kavout | AI
CVMCel-Sci Corp Latest SEC Filings - Finviz
Form DEF 14A CEL-SCI CORPORATION For: 2 July By Investing.com - Investing.com Nigeria
[ARS] CEL SCI CORP SEC Filing - Stock Titan
Equity plans and pay votes at CEL-SCI (NYSE: CVM) 2026 annual meeting - Stock Titan
Form 4 CEL-SCI Corp For: 1 July By Investing.com - Investing.com UK
CEL SCI CORP (CVM) Chief Scientific Officer receives 2,307-share stock grant - Stock Titan
CEL SCI CORP (CVM) CFO receives 4,125-share stock grant in Form 4 - Stock Titan
CEL-SCI (CVM) CEO Kersten granted 5,192 common shares at $1.04 - Stock Titan
CVM: CEL-SCI Partners with Saudi Amarox for Multikine Launch - GuruFocus
CEL-SCI signs distribution deal with Saudi Amarox for Multikine - Investing.com
Cel-Sci Corp. (CVM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cel-Sci Corp. 주식 (CVM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| KERSTEN GEERT R | Chief Executive Officer |
May 14 '26 |
Buy |
1.20 |
300,000 |
360,000 |
311,547 |
| KERSTEN GEERT R | Chief Executive Officer |
May 13 '26 |
Buy |
1.19 |
100,000 |
119,000 |
222,497 |
| KERSTEN GEERT R | Chief Executive Officer |
Jan 22 '26 |
Buy |
5.26 |
38,023 |
200,001 |
120,815 |
| KERSTEN GEERT R | Chief Executive Officer |
Dec 04 '25 |
Buy |
5.96 |
8,389 |
49,998 |
81,794 |
1.33%
1.09%
자본화:
|
볼륨(24시간):